鐣呯劧鑳跺泭鍓 5mg

诪讚讬谞讛: 住讬谉

砖驻讛: 住讬谞讬转

诪拽讜专: CFDA (鑽洃灞 - 涓浗椋熷搧鍜岃嵂鐗╃鐞嗗眬)

拽谞讛 讗转 讝讛

诪专讻讬讘 驻注讬诇:

鐩愰吀宸﹁タ鏇垮埄鍡

讝诪讬谉 诪:

婀栧崡涔濆吀鍒惰嵂鑲′唤鏈夐檺鍏徃

拽讜讚 ATC:

R06AE09

INN (砖诐 讘讬谞诇讗讜诪讬):

Levocetirizine Dihydrochloride

讻诪讜转:

5mg

讟讜驻住 驻专爪讘讟讬讜转:

鑳跺泭鍓

诪住诇讜诇 谞转讬谞讛 (砖诇 转专讜驻讜转):

鍙f湇

转讜爪专转:

婀栧崡涔濆吀鍒惰嵂鑲′唤鏈夐檺鍏徃

leaflet_short:

鏀跺綍绫诲埆: 閫氳繃璐ㄩ噺鍜岀枟鏁堜竴鑷存ц瘎浠风殑鑽搧

诪爪讘 讗讬砖讜专:

涓婂競閿鍞腑

转讗专讬讱 讗讬砖讜专:

2020-07-24

诪讗驻讬讬谞讬 诪讜爪专

                                鏍告牳鏍告牳鏍
鐩愮洂鐩愮洂鐩愮洂鐩愮洂鐩愮洂鐩愮洂
鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍
鐩愮洂鐩愮洂鐩愭牳
鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳
鏍告牳鏍告牳鏍告牳鏍
鏍告牳鏍告牳鏍
Levocetirizine Dihydrochloride Capsules
鏍告牳鏍告牳鏍
Yansuan Zuoxitiliqin Jiaonang
鏍哥洂鐩愭牳
鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍
鏍告牳鏍告牳鏍
(+)-2-[2-[4-[(4-
鏍告牳鏍
)
鏍告牳鏍
)-1-
鏍告牳鏍
]
鏍告牳鏍
]
鏍告牳
路
鏍告牳鏍告牳鏍
鏍告牳鏍告牳鏍告牳
鏍告牳鏍告牳
C
21
H
25
ClN
2
O
3
路2HCl
鏍告牳鏍告牳
461.8
鏍哥洂鐩愭牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳
鏍哥洂鐩愮洂鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳
鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳
鏍哥洂鐩愭牳
5mg
鏍哥洂鐩愮洂鐩愭牳
1
鏍
鏍告牳鏍告牳鏍告牳鏍告牳
2
鏍
鏍告牳鏍告牳鏍告牳鏍
鏍告牳鏍
6
鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍
1
鏍告牳
5mg
鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍
鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳
鏍告牳鏍告牳鏍告牳鏍
鏍告牳鏍告牳鏍告牳
ml/min
鏍
a
鏍告牳鏍告牳鏍告牳鏍
鏍告牳鏍告牳鏍告牳鏍
30-49
鏍
2
鏍告牳鏍告牳
5mg
鏍告牳鏍告牳鏍告牳鏍
<
30
鏍
3
鏍告牳鏍告牳
5mg
鏍
1
鏍
/
鏍
6
鏍
鏍告牳鏍告牳
-
鏍告牳鏍告牳鏍告牳鏍告牳鏍
<
10
鏍告牳鏍
a.
_琛琛琛琛琛琛琛 琛CLcr ml_
/
_min 琛_
=
[
140
鈭
_琛琛琛 琛 琛_
]
_脳 琛琛琛kg 琛_
72_脳 琛琛琛琛琛 mg_
/
_dl 琛_
_脳_
{
0.85_ 琛琛琛琛琛琛琛 琛_
}
鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍糕滄牳鏍告牳鏍告牳鏍告牳鈥濇牳鏍
鏍告牳鏍告牳
鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍糕滄牳鏍告牳鏍告牳鏍告牳鈥濇牳鏍告牳鏍告牳鏍
鏍哥洂鐩愮洂鐩愭牳
鏍告牳鏍告牳鏍告牳鏍告牳
鏍告牳鏍告牳鏍
鏍告牳鏍告牳鏍
6-11
鏍告牳鏍
1-6
鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告
                                
                                拽专讗 讗转 讛诪住诪讱 讛砖诇诐
                                
                            

讞讬驻讜砖 讛转专讗讜转 讛拽砖讜专讜转 诇诪讜爪专 讝讛

爪驻讜 讘讛讬住讟讜专讬讬转 讛诪住诪讻讬诐